focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
If they continue the momentum
https://www.proactiveinvestors.co.uk/companies/news/1005696/shield-therapeutics-shares-jump-13-broker-sets-punchy-price-target-1005696.html
Sky News reports that two funds managed by Barings and Farallon Capital Management have agreed to provide Vue with cash in order to pursue acquisitions.
https://www.forbes.com/sites/roystonwild/2023/02/13/cineworlds-share-price-leaps-23-on-vue-takeover-speculation/?sh=5e2962db364f
So we have a multitude of buyers at this level:
Private
Directors
Institutions
As stated if Octopus are selling down they will be out very quickly. It's one of those opportunities that come around once in a blue moon to buy a profitable company at a fraction of it's value.
I always like it when you see the head honcho in Finance buying stock. Shows confidence. At 3M Market Cap it looks very good value
Seems to be have overlooked in the current environment
People starting to see the intrinsic value in the company
https://seekingalpha.com/article/4573403-polymetal-stock-buy-the-dip-reiterate-buy
https://homeofdirectcommerce.com/news/procook-targets-market-share-growth-going-forward/
Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.
https://www.ft.com/content/9e2924d9-622f-4e60-a5d1-5dfd65ed3671?sharetype=blocked
Progress has been made. The company has repaid £2bn of debt, with about £4bn of drawn debt outstanding. It is on course to have met its financial targets for last year, including generating “modestly positive” free cash flow and mid-single-digit underlying revenue growth, but it remains a long way from firing on all cylinders.
https://www.ft.com/content/9e2924d9-622f-4e60-a5d1-5dfd65ed3671?sharetype=blocked